The Use of Renin-Angiotensin System Blockades Among Patients with Chronic Kidney Disease

Majeed Hassan  Shekhany

doi:10.56056/amj.2023.219

Authors

Majeed Hassan Shekhany MBChB, FIBMS-Medicine, lecturer of internal medicine and nephrology at Kurdistan Board of Medical Specialties, Erbil-Iraq.

DOI:

https://doi.org/10.56056/amj.2023.219

Keywords:

Angiotensin-converting enzyme inhibitors, Chronic kidney disease, End-stage renal disease

Abstract

Background and objectives: Hypertension is common in adult patients with chronic kidney disease with a prevalence that depends on the stage and etiology of chronic kidney disease and has been reported to range from 60-90%. The aim of this study was to evaluate the clinical use of renin angiotensin system blockers in chronic kidney disease patients and to identify their potential indications, contraindications and side effects amongst different clinical specialties in relation to their clinical outcomes.

Methods: This study was a descriptive cross sectional based on self-administered online questionnaire, 133 medical doctors from different specialties including nephrologists, internists, urologists, general practitioners responded to the questionnaire and filled it up, which was composed of three main parts including the socio-demographic data of the participants, data about CKD and its stages and finally the RAS blockades. The study extended from June until July 2021.

Results: The mean age ± standard deviation of respondents was 44.65 ± 6.89 years. Nearly one third of the respondents were internist, 12.8% nephrologist, 7.5% urologist and 45.9% from other different specialties. The vast majority (98.5%) of the physicians thought that renin angiotensin system inhibitors are effective anti-hypertensive agents even for chronic kidney disease patients. Most of the nephrologists and other specialties would continue the renin angiotensin system inhibitors while most of the internists and urologists would either stop or change the renin angiotensin system inhibitors, this was statistically significant and p–value was 0.010.

Downloads

Download data is not yet available.

References

Elaine E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis. 2019; 74(1): 120-31.

Hsu C, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005; 165 (8):923-8.

Schlessinger SD, Tankersley MR, Curtis JJ. Clinical Documentation of End-Stage Renal Disease Due to Hypertension. Am J Kidney Dis. 1994; 23(5):655-60.

Udani S, Lazich I, Bakris GL. Epidemiology of hypertensive kidney disease. Nat Rev Nephrol 2011; 7(1): 11–21.

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34(28):2159-219.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018;39(33):3021–104.

Oh YJ, Kim SM, Shinn BC, et at. The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease. PLoS ONE 2017;12(1): e0170874.

Yalcin AU, Kudaiberdieva G, Sahin G, et al. Patients with Hemodialysis-Induced Hypotension. Nephron Physiol 2003;93(9):21–8.

Balan DG, Stroescu AEB, Tanasescu MD, et al. Nutritional Intervention in Patients with Diabetic Renal Disease A brief presentation. Revista de Chimie 2018;69(11):3178-82.

Mandita A, Timofte D, Balcangiu-Stroescu A, et al. Treatment of High Blood Pressure in Patients with Chronic Renal Disease. Revista de Chimie 2018;70(3):615.

Doulton TW. ACE Inhibitor-Angiotensin Receptor Blocker Combinations: A Clinician's Perspective. Mini Rev Med Chem. 2006; 6(5):491-7.

Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison. Journal of the Renin-Angiotensin-Aldosterone System. 2009:195-200. doi:10.1177/1470320309352352.

Allen TJ, Campbell DJ, Cooper ME, et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. AJKD 2001; 37(5): 890-9.

Leon S J, Tangri N. The use of renin-angiotensin system inhibitors in patients with chronic kidney disease. Can J Cardiol. 2019;35(9), 1220-7.

Momoniat T, Ilyas D, Bhandari S. ACE inhibitors and ARBs: Managing potassium and renal function. Cleve Clin J Med. 2019;86(9):601-7.

Loutradis C, Price A, Ferro CJ, Sarafidis P. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. J Hum Hypertens 2021;35(6),499-509.

National Institute for Health and Care Excellence (2015). Chronic kidney disease in adults: assessment and management. NICE guideline (CG182). https://www.nice.org.uk/guidance/cg182/chapter/1-recommendations#investigations-for-chronic-kidney-disease-2.

Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin–angiotensin system blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J Am Heart Assoc 2017;6(7), e005428.

Linde C, Bakhai A, Furuland H, et al. Real?world associations of renin–angiotensin–aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new?onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc 2019;8(22); e012655.

Vejakama P, Ingsathit A, McKay GJ, et al. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients. BMC nephrology 2017;18(1):1-9.